Difference between revisions of "NextGen-O2k Exploitation"
From Bioblast
Tindle Lisa (talk | contribs) |
Tindle Lisa (talk | contribs) |
||
Line 19: | Line 19: | ||
::::'''Project Year 1:''' During the first year of the project we dedicated time to our IP strategy and successfully registered “NextGen-O2k”, “DatLab” and “High-Resolution Respirometry” as EU-trademarks. In addition to IP management and periodic IP Watch to ensure that our Freedom-to-operate (FTO) remains unimpeded, we also increased our distributor engagement. Furthermore, we explored the NextGen-O2k’s potential as a medical device and made progress on its algal biotechnology applications. The final component of WP4 for year one was the preparation for ISO certification and the implementation of new quality control measures. | ::::'''Project Year 1:''' During the first year of the project we dedicated time to our IP strategy and successfully registered “NextGen-O2k”, “DatLab” and “High-Resolution Respirometry” as EU-trademarks. In addition to IP management and periodic IP Watch to ensure that our Freedom-to-operate (FTO) remains unimpeded, we also increased our distributor engagement. Furthermore, we explored the NextGen-O2k’s potential as a medical device and made progress on its algal biotechnology applications. The final component of WP4 for year one was the preparation for ISO certification and the implementation of new quality control measures. | ||
::::'''Project Year 2:''' Year 2 was focused on ensuring processes were in place to deliver high quality and customer satisfaction. This included creating a quality policy statement as well as carrying out a customer satisfaction survey. Our Distributor Relations Dragon, Feiyuan Zhang, continued to work closely with our distributors keeping them abreast of progress and gaining valuable feedback. | ::::'''Project Year 2:''' Year 2 was focused on ensuring processes were in place to deliver high quality and customer satisfaction. This included creating a [https://wiki.oroboros.at/images/a/ac/QM_policy_2021-03-01.pdf quality policy statement] as well as carrying out a customer satisfaction survey. Our Distributor Relations Dragon, Feiyuan Zhang, continued to work closely with our distributors keeping them abreast of progress and gaining valuable feedback. | ||
== Progress and next steps == | == Progress and next steps == | ||
See » [[Talk:NextGen-O2k Exploitation|Track record]] | See » [[Talk:NextGen-O2k Exploitation|Track record]] |
Revision as of 09:38, 26 May 2021
Template:MitoFit highlights page name
The revolutionary all-in-one instrument to conquer mitochondrial disease.
WP4: Exploitation
Abstract
- Preparation for a successful market launch of the NextGen-O2k.
Achievements
- Project Year 1: During the first year of the project we dedicated time to our IP strategy and successfully registered “NextGen-O2k”, “DatLab” and “High-Resolution Respirometry” as EU-trademarks. In addition to IP management and periodic IP Watch to ensure that our Freedom-to-operate (FTO) remains unimpeded, we also increased our distributor engagement. Furthermore, we explored the NextGen-O2k’s potential as a medical device and made progress on its algal biotechnology applications. The final component of WP4 for year one was the preparation for ISO certification and the implementation of new quality control measures.
- Project Year 2: Year 2 was focused on ensuring processes were in place to deliver high quality and customer satisfaction. This included creating a quality policy statement as well as carrying out a customer satisfaction survey. Our Distributor Relations Dragon, Feiyuan Zhang, continued to work closely with our distributors keeping them abreast of progress and gaining valuable feedback.
Progress and next steps
See » Track record
The CN Beijing Huawei team representing Oroboros Instruments at Analytica China 2020. November 2020
Timea Komlodi, PhD. at an on-site visit in Linz, August 2020
Luiza Cardoza, PhD. at an on-site visit in Japan, February 2020
Snapshot of the J-Mit and ASMRM 2019
The Oroboros booth at the ASMRM & J-mit, October 2019
The first Distributor Meeting, July 2019